FBIOP Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 13, 2026
$16,86
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$6,2752 haftanın en düşüğü
$21,4352 haftanın en yükseği
Piyasa Değeri (MRQ)
$562M
P/E (TTM)
6.2
Hisse Başına Kâr (TTM)
$2.70
Gelir (TTM)
$68M
rozetleriniz
52 Haftlık Aralık
$6–$21
Analist Derecelendirmesi
BUY
Fiyat Hedefi
·
P/E
6.2
ROE
107.5%
Net Kâr Marjı
163.3%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
FBIOP Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$16.86
Piyasa Değeri (MRQ)
$562M
P/E (TTM)
6.2
Hisse Başına Kâr (TTM)
$2.70
Gelir (TTM)
$68M
Temettü Verimi
0.12%
ROE (TTM)
107.5%
D/E Borç/Özsermaye (MRQ)
0.0
52 Haftlık Aralık
$6–$21
FBIOP Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Hakkında Wikipedia'dan şirket genel bakışı
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
History
The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.
In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.
Subsidiaries
Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).
Products
Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar78
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$63M2021-12-31 → 2025-12-31
Hisse Başına Kâr$-0.072021-12-31 → 2025-12-31
Serbest Nakit Akışı·2021-12-31 → 2024-12-31
Net kar marjı163.3%2021-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | FBIOP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 6.2 | · | · | · | |
| F/S (TTM) | 8.2 | · | 16.1 | Düşük değerli | |
| F/D (MRQ) | 3.4 | · | 2.3 | Aşırı değerli | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -8.0 | · | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 4.1 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | FBIOP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -42.6% | · | -461.4% | En üst düzey | |
| EBITDA Margin (FAVÖK Marjı) | -111.0% | · | -461.4% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | 213.0% | · | -799.5% | En üst düzey | |
| Net Kâr Marjı (TTM) | 163.3% | · | -412.5% | En üst düzey | |
| ROA (TTM) | 46.9% | · | -36.6% | En üst düzey | |
| ROE (TTM) | 107.5% | · | -61.0% | En üst düzey | |
| ROIC | -138.2% | · | -64.8% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | FBIOP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.0 | · | 0.0 | Yüksek borç | |
| Cari Oran (MRQ) | 4.0 | · | 4.9 | Düşük likidite | |
| Quick Ratio (Cari Oran) | 2.2 | · | 2.7 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | FBIOP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 9.7% | · | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | -5.8% | · | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 6.8% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | FBIOP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.4 | · | 0.1 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 1.7 | · | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 3.2 | · | 5.6 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$811.1K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Temettüler Temettü verimi, ödeme oranı, temettü geçmişi, 5 Yıllık CAGR
Temettü Verimi0.12%
Temettü Ödeme Oranı9.7%
Yıllıklaştırılmış Ödeme≈$2.34
| Ex-tarihi | Miktar | Para Birimi | Temettü Verimi |
|---|---|---|---|
| Haz 14, 2024 | $0,20 | USD | ≈14.0% |
| May 14, 2024 | $0,20 | USD | ≈14.2% |
| Nis 12, 2024 | $0,20 | USD | ≈13.4% |
| Mar 14, 2024 | $0,20 | USD | ≈14.0% |
| Şub 14, 2024 | $0,20 | USD | ≈14.7% |
| Oca 11, 2024 | $0,20 | USD | ≈18.0% |
| Ara 14, 2023 | $0,20 | USD | ≈18.3% |
| Kas 14, 2023 | $0,20 | USD | ≈20.8% |
| Eki 12, 2023 | $0,20 | USD | ≈19.7% |
| Eyl 14, 2023 | $0,20 | USD | ≈19.8% |
| Ağu 14, 2023 | $0,20 | USD | ≈13.8% |
| Tem 13, 2023 | $0,20 | USD | ≈13.6% |
| Haz 14, 2023 | $0,20 | USD | ≈13.4% |
| May 12, 2023 | $0,20 | USD | ≈12.5% |
| Nis 13, 2023 | $0,20 | USD | ≈12.7% |
| Mar 14, 2023 | $0,20 | USD | ≈11.9% |
| Şub 14, 2023 | $0,20 | USD | ≈12.1% |
| Oca 12, 2023 | $0,20 | USD | ≈12.2% |
| Ara 14, 2022 | $0,20 | USD | ≈11.6% |
| Kas 14, 2022 | $0,20 | USD | ≈11.6% |
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-50.7%
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | $-0.08 | $-0.20 | 60.8% | |
| 31 Mart 2026 | $-1.13 | $-0.22 | -403.6% | |
| 31 Aralık 2025 | $-0.01 | $0.11 | -108.9% | |
| 30 Eylül 2025 | $0.11 | $-0.43 | 125.7% | |
| 30 Haziran 2025 | $-0.50 | $-0.37 | -36.2% | |
| 31 Mart 2025 | $-0.48 | $-0.50 | 4.9% | |
| 31 Aralık 2024 | $-0.75 | $-0.77 | 2.4% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Cost of Revenue | $21M | $21M | $23M | $31M | $32M | $15M | $11M | $6M | $4M | $790.0K | $0 | · | |
| R&D Expense | · | · | $106M | $135M | $129M | $64M | $81M | $87M | $48M | $35M | $30M | $10M | |
| SG&A Expense | $96M | $88M | $91M | $114M | $87M | $61M | $56M | $53M | $51M | $28M | $19M | $10M | |
| Operating Expenses | $133M | $168M | $227M | $279M | $257M | $140M | $147M | $147M | $107M | $82M | $51M | $21M | |
| Operating Income | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-90M | $-66M | $-51M | $-21M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $4M | $1M | $1M | |
| Interest Income | $2M | $3M | $3M | $1M | $649.0K | $2M | $3M | $1M | $819.0K | $298.0K | $245.0K | $662.0K | |
| Other Non-op | $18M | $1M | $-3M | $1M | $24M | $-9M | $9M | $-11M | $-8M | $-6M | $-3M | $266.0K | |
| Pretax Income | $-34M | $-121M | $-154M | $-213M | $-164M | $-103M | $-102M | $-131M | $-98M | $-71M | $-54M | · | |
| Income Tax | $-620.0K | $312.0K | $521.0K | $449.0K | $500.0K | $500.0K | $0 | $0 | $2M | $0 | $0 | · | |
| Net Income | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| EPS (Basic) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| Shares (Basic) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| EBITDA | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-100M | $-65M | $-51M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79M | $57M | $81M | $178M | $306M | $233M | $137M | $66M | $95M | $105M | $98M | $50M | |
| Short-term Investments | · | · | · | · | · | · | $0 | $18M | $36M | $0 | · | $20M | |
| Receivables | $30M | $10M | $15M | $28M | $23M | $24M | $14M | $5M | $8M | $2M | $0 | · | |
| Inventory | $10M | $14M | $10M | $14M | $10M | $1M | $857.0K | $678.0K | $171.0K | $203.0K | $0 | · | |
| Prepaid Expense | $5M | $7M | $10M | $10M | $7M | $7M | $4M | $7M | $6M | $9M | $2M | $702.0K | |
| Current Assets | $124M | $90M | $117M | $230M | $346M | $266M | $156M | $111M | $183M | $110M | $100M | $70M | |
| PP&E (Net) | $3M | $3M | $7M | $13M | $15M | $12M | $12M | $12M | $7M | $7M | $309.0K | $52.0K | |
| PP&E (Gross) | $8M | $15M | $15M | $25M | $24M | $19M | $17M | $15M | $8M | · | $377.0K | $94.0K | |
| Accum. Depreciation | $3M | $10M | $9M | $12M | $9M | $7M | $4M | $3M | $1M | · | $68.0K | $42.0K | |
| Goodwill | · | · | · | · | · | · | · | · | $19M | $19M | $0 | · | |
| Intangibles | $28M | $32M | $20M | $27M | $13M | $15M | $7M | $1M | $883.0K | $17M | $1M | $0 | |
| Other Non-current Assets | $401.0K | $731.0K | $4M | $973.0K | $1M | $1M | $1M | $276.0K | $258.0K | $394.0K | $43.0K | $64.0K | |
| Total Assets | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Accounts Payable | $14M | $32M | $35M | $57M | $47M | $11M | $35M | $34M | $27M | $2M | $10M | $366.0K | |
| Accrued Liabilities | $47M | $66M | $74M | $97M | $91M | $45M | $25M | $16M | $18M | $10M | $9M | $4M | |
| Short-term Debt | · | · | · | · | · | $0 | $7M | · | · | · | · | $0 | |
| Current Liabilities | $50M | $71M | $85M | $128M | $101M | $52M | $46M | $56M | $71M | $57M | $11M | $4M | |
| Capital Leases | $13M | $15M | $18M | $22M | $21M | $23M | $24M | $0 | · | · | · | · | |
| Deferred Tax | · | · | $233.0K | $0 | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $5M | $5M | $5M | $584.0K | $722.0K | |
| Total Liabilities | $123M | $146M | $166M | $244M | $171M | $136M | $154M | $121M | $125M | $88M | $34M | $19M | |
| Long-term Debt | $54M | $58M | $61M | $92M | $43M | $52M | $85M | $84M | $68M | $30M | $24M | $14M | |
| Total Debt | · | · | · | · | · | $0 | · | · | · | · | · | · | |
| Common Stock | $31.0K | $28.0K | $15.0K | $7.0K | $101.0K | $95.0K | $74.0K | $58.0K | $51.0K | $49.0K | $47.0K | $46.0K | |
| Paid-in Capital | $784M | $764M | $717M | $676M | $656M | $583M | $462M | $397M | $364M | $284M | $247M | $212M | |
| Retained Earnings | $-734M | $-741M | $-695M | $-634M | $-547M | $-483M | $-436M | $-396M | $-312M | $-245M | $-190M | $-142M | |
| Stockholders' Equity | $50M | $23M | $23M | $42M | $109M | $100M | $26M | $2M | $53M | $38M | $57M | $71M | |
| Liabilities + Equity | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Shares Outstanding | 31,364,094 | 27,908,839 | 15,093,053 | 7,366,283 | 101,435,505 | 94,877,492 | 74,027,425 | 57,845,447 | 50,991,285 | 48,932,023 | 47,147,032 | 46,494,034 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | $1M | $944.0K | $26.0K | $23.0K | |
| Stock-based Comp | $29M | $33M | $17M | $23M | $19M | $13M | $13M | $15M | $13M | $12M | $14M | $6M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $0 | $-73.0K | $0 | $0 | |
| Amort. of Intangibles | $4M | $3M | $4M | $4M | · | $1M | $1M | · | $2M | $0 | $0 | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | $-34M | $-4M | $14M | · | |
| Operating Cash Flow | $-66M | $-80M | $-128M | $-179M | $-117M | $-84M | $-95M | $-99M | $-81M | $-46M | $-20M | $-16M | |
| CapEx | · | $0 | $63.0K | $3M | $5M | $2M | $2M | $7M | $648.0K | $6M | $283.0K | $0 | |
| Investing Cash Flow | $10M | $-15M | $-2M | $-23M | $41M | $-7M | $20M | $19M | $-40M | $-6M | $8M | · | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Issued | $1M | $4M | $2M | $6M | $9M | $46M | $21M | $10M | · | $0 | $0 | $4M | |
| Stock Repurchased | · | · | · | · | · | $70.0K | $0 | · | · | · | · | · | |
| Net Stock Activity | $1M | $4M | $2M | $6M | $9M | $47M | · | $10M | · | $0 | $0 | · | |
| Dividends Paid | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $77M | $71M | $33M | $75M | $149M | $172M | $147M | $51M | $150M | $43M | $61M | · | |
| Net Change in Cash | $22M | $-25M | $-98M | $-127M | $73M | $82M | $72M | $-29M | $29M | $-9M | $48M | $-50M | |
| Taxes Paid | $49.0K | $120.0K | $-55.0K | $858.0K | $993.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-80M | $-128M | $-182M | $-121M | $-86M | $-97M | $-106M | $-88M | $-52M | $-21M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | $-93M | · | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.9% | -398.7% | -5855.3% | · | |
| Net Margin | 10.8% | -79.8% | -71.8% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -35.6% | -334.3% | -5611.6% | · | |
| Pretax Margin | -53.0% | -209.0% | -181.8% | -281.8% | -238.9% | -225.6% | -277.5% | -486.6% | -52.4% | · | · | · | |
| EBITDA Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.3% | -393.0% | -5852.3% | · | |
| ROA | 4.1% | -33.9% | -26.3% | -25.1% | -17.7% | -16.7% | -21.8% | -43.5% | -32.1% | -34.8% | -47.1% | · | |
| ROE | 18.8% | -203.2% | -188.7% | -115.1% | -61.9% | -73.5% | -284.8% | -309.2% | -146.9% | -115.6% | -76.0% | · | |
| ROIC | -138.2% | -486.7% | -633.5% | -488.9% | -174.0% | -94.1% | -422.7% | -6479.3% | -195.5% | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.3 | 1.4 | 1.8 | 3.4 | 5.5 | 3.4 | 2.0 | 2.7 | 1.9 | 9.4 | · | |
| Quick Ratio | 2.2 | 0.9 | 1.1 | 1.6 | 3.3 | 5.3 | 3.3 | 1.6 | 2.3 | 1.6 | 9.3 | · | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -17.3 | -17.8 | -34.1 | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.9 | 0.1 | 0.0 | · | |
| Inventory Turnover | 1.7 | 1.7 | 2.2 | 2.6 | 5.7 | 12.9 | 13.7 | 14.4 | 19.6 | -7.8 | · | · | |
| Receivables Turnover | 3.2 | 4.5 | 3.9 | 3.0 | 2.9 | 2.8 | 3.8 | 4.1 | 39.1 | 18.0 | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.59 | $0.81 | $1.49 | $0.38 | $1.07 | $1.06 | $0.35 | $0.03 | $1.03 | $0.79 | $1.21 | · | |
| Revenue / Share | $2.27 | $2.77 | $10.42 | $0.85 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.36 | $-3.86 | $-15.81 | $-2.02 | · | · | · | · | · | · | · | · | |
| Cash / Share | $2.53 | $2.05 | $5.36 | $1.61 | $3.01 | $2.46 | $1.85 | $1.13 | $2.23 | $1.80 | $2.08 | · | |
| EPS (TTM) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 9.7% | -31.8% | 11.6% | 10.1% | 50.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -5.8% | -5.7% | 22.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Net Income TTM | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| Market Cap | $298M | $186M | $179M | $1.95B | $2.63B | $1.84B | $1.52B | $832M | $1.16B | · | · | · | |
| Enterprise Value | · | · | · | · | · | $1.61B | · | · | · | · | · | · | |
| P/E | -135.6 | -2.5 | -1.4 | -1.1 | -32.8 | · | · | · | · | · | · | · | |
| P/S | 4.7 | 3.2 | 2.1 | 25.7 | 38.2 | 40.3 | 41.4 | 31.0 | 67.3 | · | · | · | |
| P/B | 6.0 | 8.2 | 7.9 | 46.7 | 24.2 | 18.3 | 57.8 | 449.4 | 22.1 | · | · | · | |
| P / Tangible Book | 13.4 | · | 79.4 | 134.3 | 27.3 | 21.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.5 | -2.3 | -1.4 | -10.9 | -22.5 | -22.0 | -16.0 | -8.4 | -13.6 | · | · | · | |
| P / FCF | · | -2.3 | -1.4 | -10.7 | -21.7 | -21.5 | -15.6 | -7.9 | -13.3 | · | · | · | |
| EV / EBITDA | · | · | · | · | · | -17.0 | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | -18.8 | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | 35.2 | · | · | · | · | · | · | |
| Dividend Yield | 0.22% | 0.37% | 0.41% | 0.04% | 0.03% | 0.01% | 0.00% | · | · | · | · | · | |
| Earnings Yield | -0.74% | -40.5% | -71.4% | -90.5% | -3.0% | · | · | · | · | · | · | · | |
| Payout Ratio | 9.7% | -1.5% | -1.2% | -0.87% | -1.2% | -0.51% | · | · | · | · | · | · | |
| Annual Payout | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $16M | $16M | $18M | $16M | $13M | $15M | $15M | $15M | $13M | $20M | $35M | $17M | $12M | $16M | $17M | |
| Cost of Revenue | $6M | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $6M | $6M | $2M | $6M | $8M | $6M | $8M | $7M | |
| R&D Expense | · | · | · | · | · | · | · | $9M | $13M | $25M | · | $20M | $32M | $40M | $35M | $30M | |
| SG&A Expense | $21M | $16M | $15M | $17M | $39M | $26M | $27M | $22M | $21M | $18M | $19M | $22M | $24M | $25M | $28M | $30M | |
| Operating Expenses | $29M | $24M | $21M | $24M | $53M | $35M | $39M | $37M | $43M | $50M | $40M | $49M | $67M | $71M | $71M | $67M | |
| Operating Income | $-10M | $-8M | $-5M | $-7M | $-36M | $-22M | $-24M | $-22M | $-28M | $-37M | $-20M | $-14M | $-50M | $-59M | $-55M | $-51M | |
| Interest Income | $2M | $570.0K | $637.0K | $736.0K | $622.0K | $490.0K | $527.0K | $589.0K | $734.0K | $833.0K | $705.0K | $547.0K | $715.0K | $1M | $687.0K | $419.0K | |
| Other Non-op | $11M | $1M | $-20.0K | $18M | $-62.0K | $-12.0K | $-14.0K | $1M | $282.0K | $-21.0K | $-5M | $620.0K | $395.0K | $304.0K | $6M | $648.0K | |
| Pretax Income | $922.0K | $142M | $-6M | $9M | $-12M | $-25M | $-26M | $-27M | · | · | $-29M | $-11M | · | · | $-57M | $-53M | |
| Income Tax | $320.0K | $5M | $-646.0K | $26.0K | $0 | $0 | $243.0K | $69.0K | $0 | $0 | $380.0K | $141.0K | $0 | $0 | $449.0K | $0 | |
| Net Income | $-468.0K | $110M | $-4M | $6M | $15M | $-11M | $-7M | $-13M | $-11M | $-15M | $-9M | $-5M | $-25M | $-22M | $-27M | $-23M | |
| EPS (Basic) | $-0.08 | $3.44 | $-0.22 | $0.13 | $0.50 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-0.41 | $-0.94 | $-3.65 | $-3.47 | $-11.39 | $-4.11 | |
| EPS (Diluted) | $-0.08 | $2.82 | $-0.15 | $0.11 | $0.45 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-3.67 | $-0.94 | $-3.65 | $-0.21 | $-11.42 | $-4.11 | |
| Shares (Basic) | 31,791,173 | 31,540,595 | · | 27,244,474 | 26,879,380 | 26,450,218 | · | 19,697,290 | 18,316,874 | 17,151,945 | · | 7,498,653 | 7,377,332 | 6,792,376 | · | 5,961,663 | |
| Shares (Diluted) | 31,791,173 | 38,412,716 | · | 33,100,961 | 29,824,182 | 26,450,218 | · | 19,697,290 | 18,316,874 | 17,151,945 | · | 7,498,653 | 7,377,332 | 101,885,648 | · | 5,961,663 | |
| EBITDA | $-10M | $-8M | · | $-7M | $-36M | $-22M | · | $-22M | $-28M | $-37M | · | $-14M | $-50M | $-59M | · | $-51M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $197M | $256M | $79M | $86M | $74M | $91M | $57M | $59M | $76M | $84M | $81M | $72M | $78M | $152M | $178M | $208M | |
| Receivables | $36M | $25M | $30M | $18M | $16M | $18M | $10M | $11M | $10M | $10M | $15M | $8M | $17M | $28M | $28M | $29M | |
| Inventory | $8M | $9M | $10M | $12M | $13M | $12M | $14M | $12M | $10M | $11M | $10M | $11M | $12M | $13M | $14M | $15M | |
| Prepaid Expense | $4M | $5M | $5M | $2M | $7M | $5M | $7M | $3M | $5M | $12M | $10M | $6M | $7M | $8M | $10M | $6M | |
| Current Assets | $246M | $295M | $124M | $119M | $110M | $127M | $90M | $86M | $103M | $117M | $117M | $98M | $128M | $202M | $230M | $258M | |
| PP&E (Net) | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $6M | $7M | $7M | $7M | $12M | $13M | $14M | |
| PP&E (Gross) | $7M | $7M | $8M | $8M | $8M | $8M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $25M | $25M | $25M | |
| Accum. Depreciation | $3M | $2M | $3M | $3M | $3M | $3M | $10M | $12M | $10M | $9M | $9M | $9M | $8M | $13M | $12M | $12M | |
| Intangibles | $26M | $26M | $28M | $29M | $30M | $31M | $32M | $18M | $19M | $19M | $20M | $21M | $22M | $26M | $27M | $28M | |
| Other Non-current Assets | $1M | $740.0K | $401.0K | $18M | $3M | $3M | $731.0K | $3M | $3M | $4M | $4M | $5M | $4M | $943.0K | $973.0K | $1M | |
| Total Assets | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Accounts Payable | $12M | $14M | $14M | $19M | $20M | $28M | $32M | $34M | $38M | $42M | $35M | $45M | $49M | $66M | $57M | $56M | |
| Accrued Liabilities | $49M | $93M | $47M | $45M | $49M | $66M | $66M | $64M | $69M | $76M | $74M | $81M | $99M | $105M | $97M | $94M | |
| Short-term Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $62M | $103M | $50M | $54M | $58M | $74M | $71M | $70M | $76M | $88M | $85M | $97M | $129M | $129M | $128M | $106M | |
| Capital Leases | $11M | $12M | $13M | $13M | $13M | $14M | $15M | $15M | $16M | $18M | $18M | $19M | $20M | $21M | $22M | $21M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Other Non-current Liabilities | $3M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $111M | $154M | $123M | $116M | $123M | $146M | $146M | $140M | $160M | $169M | $166M | $164M | $197M | $244M | $244M | $222M | |
| Long-term Debt | $35M | $38M | $52M | $48M | $50M | $56M | $58M | $52M | $67M | $61M | $61M | $46M | $55M | $92M | $92M | $91M | |
| Total Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $33.0K | $33.0K | $31.0K | $31.0K | $30.0K | $30.0K | $28.0K | $28.0K | $23.0K | $19.0K | $15.0K | $9.0K | $132.0K | $130.0K | $7.0K | $108.0K | |
| Paid-in Capital | $788M | $786M | $784M | $786M | $780M | $774M | $764M | $755M | $739M | $733M | $717M | $702M | $699M | $693M | $676M | $669M | |
| Retained Earnings | $-624M | $-624M | $-734M | $-730M | $-736M | $-751M | $-741M | $-734M | $-721M | $-710M | $-695M | $-686M | $-681M | $-656M | $-634M | $-607M | |
| Stockholders' Equity | $164M | $162M | $50M | $56M | $44M | $22M | $23M | $21M | $18M | $23M | $23M | $17M | $19M | $38M | $42M | $62M | |
| Liabilities + Equity | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Shares Outstanding | 33,311,012 | 33,186,671 | 31,364,094 | 31,005,170 | 29,752,795 | 29,554,966 | 27,908,839 | 27,584,600 | 22,587,038 | 19,375,343 | 15,093,053 | 8,937,587 | 131,657,369 | 130,417,161 | 7,366,283 | 108,259,353 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $2M | $2M | $3M | $17M | $6M | $16M | $7M | $5M | $5M | $4M | $4M | $4M | $5M | $6M | $7M | |
| Amort. of Intangibles | $969.0K | $1M | $1M | $1M | $1M | $1M | $982.0K | $814.0K | $814.0K | $814.0K | $815.0K | $814.0K | $1M | $1M | $1M | $1M | |
| Operating Cash Flow | $-59M | $204M | $-13M | $-6M | $-28M | $-20M | $-13M | $-20M | $-22M | $-25M | $-35M | $-17M | $-33M | $-43M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | $0 | · | · | $28.0K | $1.0K | $34.0K | $0 | $91.0K | $980.0K | |
| Investing Cash Flow | $-79.0K | $0 | $0 | $3M | $6M | $1M | $-15M | $0 | $0 | $0 | $-63.0K | $5M | $-2M | $-5M | $-391.0K | $-893.0K | |
| Stock Issued | · | $0 | $0 | $0 | $-1.0K | $1M | $340.0K | $568.0K | $2M | $894.0K | $-15.0K | $888.0K | $721.0K | $447.0K | $303.0K | $223.0K | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | $894.0K | · | · | · | $447.0K | · | · | |
| Dividends Paid | · | $0 | $166.0K | $166.0K | $166.0K | $166.0K | $166.0K | $176.0K | $176.0K | $176.0K | $180.0K | $185.0K | $185.0K | $186.0K | $186.0K | $188.0K | |
| Financing Cash Flow | $91.0K | $-27M | $6M | $15M | $5M | $52M | $26M | $3M | $14M | $28M | $44M | $-3M | $-30M | $22M | $19M | $4M | |
| Net Change in Cash | $-59M | $176M | $-7M | $12M | $-17M | $34M | $-2M | $-17M | $-8M | $2M | $9M | $-14M | $-66M | $-26M | $-30M | $-40M | |
| Taxes Paid | · | · | $0 | $0 | · | · | $5.0K | $0 | $115.0K | $0 | $-38.0K | $35.0K | $52.0K | $-104.0K | $-604.0K | $1M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-43M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| Net Margin | -2.5% | 688.2% | · | 33.2% | 94.3% | -80.5% | · | -88.0% | -73.5% | -118.3% | · | -14.5% | -142.5% | -173.3% | · | -136.2% | |
| Pretax Margin | 4.9% | 887.2% | · | 50.2% | · | · | · | -182.0% | · | · | · | -30.4% | · | · | · | · | |
| EBITDA Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| ROA | -0.20% | 41.3% | · | 3.8% | 10.1% | -6.2% | · | -9.3% | -6.7% | -7.2% | · | -2.1% | -9.1% | -6.4% | · | -6.2% | |
| ROE | -0.45% | 119.7% | · | 15.2% | 50.1% | -46.8% | · | -68.0% | -60.2% | -50.7% | · | -12.9% | -51.8% | -31.8% | · | -29.2% | |
| ROIC | -3.9% | -4.5% | · | -12.2% | · | · | · | -104.7% | · | · | · | -83.6% | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.9 | · | 2.2 | 1.9 | 1.7 | · | 1.2 | 1.4 | 1.3 | · | 1.0 | 1.0 | 1.6 | · | 2.4 | |
| Quick Ratio | 3.8 | 2.7 | · | 1.9 | 1.6 | 1.5 | · | 1.0 | 1.1 | 1.1 | · | 0.8 | 0.7 | 1.4 | · | 2.2 | |
| Debt / Equity | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.5 | 0.4 | 0.4 | · | 0.5 | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.4 | · | 0.5 | |
| Receivables Turnover | 0.7 | 0.7 | · | 1.2 | 1.3 | 0.9 | · | 1.6 | 1.1 | 0.7 | · | 1.9 | 0.8 | 0.4 | · | 0.5 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.93 | $4.89 | · | $1.80 | $1.48 | $0.75 | · | $0.77 | $0.79 | $1.19 | · | $1.87 | $0.14 | $0.29 | · | $0.57 | |
| Revenue / Share | $0.59 | $0.42 | · | $0.53 | $0.55 | $0.50 | · | $0.74 | $0.81 | · | · | $4.63 | $0.16 | $0.12 | · | $0.18 | |
| Cash Flow / Share | · | $5.31 | · | · | · | $-0.74 | · | · | · | · | · | · | · | $-0.42 | · | · | |
| Cash / Share | $5.90 | $7.71 | · | $2.78 | $2.50 | $3.09 | · | $2.13 | $3.37 | $4.32 | · | $8.09 | $0.59 | $1.17 | · | $1.92 | |
| Dividend / Share | · | · | · | · | · | · | · | $0.00 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $2.70 | $3.23 | · | $-0.08 | $-0.95 | $-2.13 | · | $-6.20 | $-6.38 | $-9.30 | · | $-16.22 | $-19.39 | $-16.00 | · | $-4.93 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $66M | · | $62M | $59M | $58M | · | $63M | $83M | $85M | · | $81M | $63M | $64M | · | $78M | |
| Net Income TTM | $112M | $128M | · | $4M | $-15M | $-41M | · | $-49M | $-41M | $-55M | · | $-78M | $-96M | $-92M | · | $-91M | |
| Market Cap | $670M | $462M | · | $285M | $229M | $178M | · | $150M | $359M | $322M | · | $105M | $2.30B | $2.40B | · | $2.03B | |
| Enterprise Value | $478M | $208M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 7.4 | 4.3 | · | -115.0 | -8.1 | -2.8 | · | -0.9 | -2.5 | -1.8 | · | -0.7 | -0.9 | -1.1 | · | -3.8 | |
| P/S | 9.8 | 7.0 | · | 4.6 | 3.9 | 3.1 | · | 2.4 | 4.3 | 3.8 | · | 1.3 | 36.7 | 37.4 | · | 26.2 | |
| P/B | 4.1 | 2.8 | · | 5.1 | 5.2 | 8.0 | · | 7.1 | 20.1 | 14.0 | · | 6.3 | 124.5 | 63.5 | · | 32.9 | |
| P / Tangible Book | 4.8 | 3.4 | · | 10.5 | 16.1 | · | · | 45.4 | · | 90.5 | · | · | · | 205.7 | · | 61.1 | |
| P / Cash Flow | · | 2.3 | · | · | · | -9.1 | · | · | · | -12.7 | · | · | · | -55.5 | · | · | |
| EV / Revenue | 7.0 | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend Yield | 0.07% | 0.11% | · | 0.23% | 0.29% | 0.39% | · | 0.47% | 0.20% | 0.23% | · | 0.71% | 0.03% | 0.03% | · | 0.04% | |
| Earnings Yield | 13.4% | 23.2% | · | -0.87% | -12.3% | -35.4% | · | -113.8% | -40.1% | -56.0% | · | -138.3% | -110.8% | -87.0% | · | -26.3% | |
| Payout Ratio | · | 0.00% | · | · | · | -1.6% | · | · | · | -1.1% | · | · | · | -0.86% | · | · | |
| Annual Payout | $498.0K | $498.0K | · | $664.0K | $674.0K | $684.0K | · | $708.0K | $717.0K | $726.0K | · | $742.0K | $745.0K | $748.0K | · | $750.0K |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Gelir | $63M | · | · | $58M | · |
| Faaliyet Kâr Marjı % | -111.0% | · | · | -191.4% | · |
| Net Gelir | $7M | · | · | $-46M | · |
| Seyreltilmiş Hisse Başı Kâr | $-0.07 | · | · | $-2.69 | · |
| Metrik | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Cari Oran | 2.5 | · | · | 1.3 | · |
| Cari Oran | 2.2 | · | · | 0.9 | · |
| Metrik | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | · | · | · | $-80M | · |
Aktivistler ve %5+ sahipler 3 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. ×2 başvurular | 03 Ocak 2025 | 12,40% | Değişiklik | · | SEC |
| Lindsay A Rosenwald, M.D. | 27 Ocak 2017 | · | İlk başvuru | · | SEC |
| Michael S. Weiss | 28 Ocak 2016 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 10 içeriden öğrenenler · 4 yöneticiler · 8 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | President and CEO | 01 Ocak 2017 A | 5.857.168 | 0 | 0 | $0 |
| David Jin | Chief Financial Officer | 01 Ekim 2026 A | 1.652.761 | 0 | 0 | $0 |
| Michael S Weiss | Exec. VC - Strategic Dev. | 01 Ocak 2017 A | 8.001.170 | 0 | 0 | $0 |
| George Avgerinos | SVP, Biologics Operations | 16 Eylül 2016 S | 259.088 | 0 | 0 | $0 |
| Kevin Lorenz | Yönetim kurulu üyesi | 01 Ocak 2026 A | 101.009 | 0 | 0 | $0 |
| Dov Klein | Yönetim kurulu üyesi | 14 Temmuz 2017 A | 201.668 | 0 | 0 | $0 |
| Jimmie Harvey | Yönetim kurulu üyesi | 10 Mart 2017 A | · | 0 | 0 | $0 |
| Malcolm Hoenlein | Yönetim kurulu üyesi | 10 Mart 2017 A | · | 0 | 0 | $0 |
| Eric K Rowinsky | Yönetim kurulu üyesi | 01 Ocak 2017 A | 350.000 | 0 | 0 | $0 |
| Jay J Lobell | Yönetim kurulu üyesi | 01 Ocak 2017 A | 686.000 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
FBIOP Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 8 analist
AL
2 25,0%
Güçlü Al
5 62,5%
Al
1 12,5%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| FBIOP | $298M | -135.6 | 9.7% | 10.8% | 18.8% | · |
| ALDX | $312M | -9.2 | · | · | -68.0% | · |
| SPRO | $131M | 15.5 | 39.2% | 12.8% | 18.7% | · |
| RNTX | · | -0.6 | · | · | · | · |
| GRML | · | · | · | · | -104.9% | · |
| FBIO | · | · | · | · | · | · |
| XBIT | · | -1.6 | · | · | · | · |
| APLM | · | -2.5 | · | -128.7% | -1305.4% | · |
| IBIO | $97M | -5.5 | -75.0% | -33044.0% | -65.7% | · |
| GOSS | $724M | -4.1 | -57.7% | -351.5% | 201.8% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 13, 2026